secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069804
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss $12.8M; on track for cytisinicline NDA submission to FDA in June 2025
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities totaled $23.2M; operating expenses $12.9M for Q1 2025.
- Plans to submit NDA for cytisinicline to FDA in June 2025; ORCA-3 results published in JAMA Internal Medicine.
- ORCA-OL long-term safety trial met FDA requirements: >300 patients with 6 months, >100 with 1 year treatment.
- DSMC third safety review found no concerns; SAB meeting held in May 2025 with ten nicotine cessation experts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000095017025069804/0000950170-25-069804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000095017025069804/achv-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer